LYPQOZET Drug Patent Profile
✉ Email this page to a colleague
When do Lypqozet patents expire, and when can generic versions of Lypqozet launch?
Lypqozet is a drug marketed by Pharmobedient and is included in one NDA.
The generic ingredient in LYPQOZET is atorvastatin calcium; ezetimibe. There is one drug master file entry for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LYPQOZET?
- What are the global sales for LYPQOZET?
- What is Average Wholesale Price for LYPQOZET?
Summary for LYPQOZET
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | LYPQOZET at DailyMed |
US Patents and Regulatory Information for LYPQOZET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmobedient | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-001 | Apr 26, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-004 | Apr 26, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-002 | Apr 26, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-003 | Apr 26, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
